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Hereditary nephropathic systemic amyloidosis caused by a novel vari-
ant apolipoprotein A-I. We report a family with autosomal-dominant
hereditary systemic amyloidosis in three generations, presenting with renal
involvement. Two members of the current generation received renal
transplants for end-stage renal failure 16 and 18 years ago, and remain
very well clinically despite massive visceral amyloidosis. Two other mem-
bers of this generation, aged 32 and 47 years, have massive systemic
amyloid but no clinical disability. Individuals known to be affected in
previous generations died of renal failure in early adult life. Amyloid
deposits in the proband, one of the transplanted individuals, were
composed of apolipoprotein A-I (apoA-I), and among living family
members there was complete concordance between amyloidosis and the
presence of a novel 9 base pair in-frame deletion mutation in exon 4 of the
apoA-I gene, causing a loss of residues Glu70Phe71Trp72. This predicts
the acquisition of a single extra positive charge by mature apoA-I, and this
variant was detected in the plasma of all carriers. All the previously
reported amyloidogenic variants of apoA-I also carry an extra positive
charge, indicating that this electrostatic change is likely to be relevant to
the amyloidogenicity of apoA-I.
Hereditary non-neuropathic systemic amyloidosis is a very rare
autosomal dominant condition that causes serious morbidity and,
until recently has always been fatal [1]. There is widespread
deposition of amyloid in the tissues but the major clinical prob-
lems are related to renal, cardiac and hepatic involvement. There
is considerable variation in clinical phenotypic and patterns of
organ damage between families and also sometimes within kin-
dreds. Mutations encoding single residue substitutions in apoA-I
[2–6], fibrinogen a-chain [7, 8] and lysozyme [9] are the cause of
the condition in different kindreds, but there is no clear relation-
ship between the amyloid fibril protein and the clinical manifes-
tations. We recently reported the first case of hereditary amyloid-
osis caused by a deletion rather than a single point mutation, and
this was also in the apoA-I gene [5]. Here we describe another
kindred in which there is a different, previously unreported
deletion mutation in apoA-I. It causes predominantly renal
amyloidosis, and, despite extensive deposits elsewhere, patients
whose lives have been greatly prolonged by renal transplantation
have suffered remarkably little from other manifestations. Apart
from their curious and interesting phenotypes, and the impor-
tance for management and counseling of the affected families,
identification and characterization of these rare hereditary syn-
dromes is of importance because of the information it may yield
about the molecular pathology of amyloidosis in general.
METHODS
Proband
A 43-year-old woman (AA) developed mild hypertension,
proteinuria and hepatosplenomegaly with normal liver function,
at the age of 18 years. Renal function progressively declined and
she commenced hemodialysis at the age of 23, undergoing suc-
cessful renal transplantation from a live-related donor four years
later. The renal graft continues to function satisfactorily 17 years
later, although the serum creatinine has risen recently to 160
mmol/liter. A mild, persistent but non-progressive derangement of
liver enzymes was noted several years after presentation, but
synthetic liver function has remained normal. Routine blood
biochemistry and lipid studies are otherwise normal, although the
serum apoA-I is slightly low (66 mg/dl, normal range 100 to 170
mg/dl). Renal and liver biopsies at presentation had both shown
amyloid, and a transplant biopsy within the first month had shown
mild acute rejection but no recurrence of amyloid. The electro-
cardiogram has always been normal, and there has never been
clinical evidence of peripheral or autonomic neuropathy. Over the
last 13 years she has developed bilateral central scotomata with
areas of retinal atrophy, thought to be consistent with an amyloid
vasculopathy of the retinal or choroidal vessels. Visual acuity has
declined to 6/30 in both eyes. Fluorescein angiography failed to
demonstrate any leakage from retinal vessels.
Kindred
The mother (SJ) of the proband died from chronic renal failure
in “middle age.” Autopsy demonstrated amyloid involvement of
all major viscera. The maternal grandfather (TG) and his first
cousin (OT) had both died young from unspecified renal disease.
The sister (SP, age 47 years) of the proband has biopsy-proven
amyloid of the liver and kidneys, having been investigated because
1 See Editorial by Benson, p 509
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Fig. 1. Whole body scintigraphic images after intravenous injection of 131I-human SAP. There is heavy amyloid deposition in the liver and spleen in
the proband (AA), in her sister (SP) and in her two cousins (JF and BF). The faint thyroid images result from incomplete blockade of the gland with
cold iodide, and the bladder, containing degradation products of the tracer, is also seen in some scans. Extravasation of injected tracer is seen in the
left antecubital fossa of JF. The images of RF and KW show no amyloid and are normal.
of the family history. She has hepatomegaly but is otherwise well
clinically and biochemically, with no proteinuria. There is one
brother (KW, age 43 years) who is clinically well and has not
previously been investigated.
The maternal aunt (CF) of the proband died in renal failure at
the age of 32 years, with extensive visceral amyloid at autopsy.
One (JF, age 41 years) of her three children, the first cousins of
the proband, had systemic amyloidosis diagnosed at the age of 21
years after presenting with mild hypertension and proteinuria, and
progressed to chronic renal failure and then renal transplantation
at the age of 27. She also has retinopathy, but 15 years later she
remains well, apart from hypertension, with a functioning renal
transplant. One brother (RF, age 37 years) is completely well and
a rectal biopsy was negative for amyloid many years previously. A
second brother (BF, age 32 years) is well and has not previously
been investigated.
Scintigraphy with iodinated serum amyloid P component
Serum amyloid P component (SAP) binds avidly and specifi-
cally to all types of amyloid fibrils, and radiolabeled pure SAP is
a quantitative in vivo probe for detection and monitoring of
amyloid deposits [10]. For the present study SAP was labeled with
the longer half life isotope 131I rather than the usual 123I in order
to permit scintigraphy after shipment of the tracer by air to South
Africa. Each of the six patients investigated received an intrave-
nous injection of 37 MBq (5 mSv) of 131I-SAP and underwent
anterior and posterior whole body gamma-camera scanning 24
hours later.
Histology and immunohistochemistry
Formalin-fixed paraffin embedded liver biopsy and rectal biop-
sies were available from the proband and rectal biopsies from her
five siblings and cousins. No other tissue could be traced. Amyloid
was identified by its pathognomonic green birefringence in 6 mm
sections stained with alkaline alcohol Congo red [11] viewed in
crossed polarized light. Immunohistochemical staining for apoA-I
in tissue sections (6 mm) was performed exactly as previously
described, using a well defined monospecific anti-apoA-I anti-
serum. Other sections were processed similarly using anti-human
lysozyme as the primary antiserum. No further tissue was available
for additional immunohistochemical studies.
Detection of variant apoA-I
Charge variant isoforms of apoA-I were sought, as previously
described [3], by isoelectric focusing of delipidated whole plasma
in urea-agarose gel followed by pressure blotting onto 0.45 mm
nitro-cellulose membrane (Hybond ECL; Amersham Interna-
tional plc, Little Chalfont, Bucks, UK) for 90 minutes. Immuno-
staining with goat anti-human apoA-I antiserum (1:20,000, Medix
Biotech) and horseradish peroxidase-labeled rabbit anti-goat IgG
antibody (1:10,000, Dako Ltd) was detected by enhanced chemi-
luminescence (ECL, Amersham) according to the manufacturer’s
Western blotting protocol.
Direct DNA sequencing
DNA was extracted from the blood of the proband and two
fragments of the apoA-I gene, comprising the region encoding the
N-terminal region of apoA-I, were amplified by PCR and the
nucleotide sequence determined, all as reported elsewhere [3].
The 59 end of exon 4 was found to contain a 9 bp deletion in one
allele, allowing easy detection of the abnormal PCR product on an
8% polyacrylamide gel.
Plasma lipid studies
Plasma apoA-I and apoB were estimated in fasting samples by
Bayer immunoturbidimetric methods and triglyceride, cholesterol
and low density lipoprotein (LDL) and high density lipoprotein
(HDL) cholesterol by standard clinical chemistry methods.
RESULTS
Serum amyloid P component scintigraphy
The scans (Fig. 1) demonstrated amyloid deposits in the liver
and spleen of the proband; the transplant kidney was not visual-
ized. A similar distribution was seen in her sister (SP) and the
signal from these viscera obscured any from her native kidneys.
The scan of her brother (KW) was normal. Among the cousins,
there were massive amyloid deposits in the liver of JF, with a
lesser signal in the spleen and equivocal signal in the transplant
kidney. The scan was normal in the brother RF, in accordance
with the previous biopsy findings, but his clinically unaffected
brother (BF) had massive visceral deposits. The family tree is
shown in Figure 2.
Histology and immunohistochemistry
Amyloid deposits almost completely replaced normal liver
tissue in the proband’s liver biopsy, and stained intensely with
antiserum to apoA-I (Fig. 3). The staining was completely abol-
ished by prior absorption of the antiserum with human high
density lipoprotein (Fig. 3). ApoA-I is thus the major component
of the amyloid fibrils. There was no staining with anti-lysozyme
antiserum. The only amyloid present in the rectal biopsies was a
tiny deposit in one (JF) and immunohistochemistry was not
attempted.
ApoA-I gene deletion mutation
Sequencing of the apoA-I gene from the proband revealed that
she was heterozygous for a mutation in exon 4 in which 9
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Fig. 2. Family tree of the affected kindred. Solid symbols, individuals with
confirmed amyloid; shaded symbols, individuals suspected of having had
amyloid; open symbols, unaffected subjects.
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nucleotides had been deleted from the wild type sequence (Fig. 4).
The mutation was readily detected by polyacrylamide gel analysis
of the exon 4 PCR product (Fig. 5), and this test was used to
screen family members. The in-frame deletion encoded loss of
residues Glu70Phe71Trp72, predicting acquisition by the variant
apoA-I molecule of one additional positive charge compared to
the wild-type amino acid sequence. The concordance of the
mutation with clinical, histological and scintigraphic evidence of
amyloid is shown in Table 1.
Charge variant apoA-I in plasma
The plasma of carriers of the mutation contained the normal
isoforms of wild type apoA-I and also variant apoA-I with a pI
corresponding to one extra positive charge (Fig. 6, lanes 1, 2, 4
and 5). The variant was significantly less abundant than wild type
apoA-I, especially in one individual (lane 2, BF). The variant was
not detected in unaffected family members. Total apoA-I levels
were below normal in all carriers of the mutant gene and were also
slightly reduced in the two family members who did not carry the
mutant gene (Table 2). ApoB and the other lipid parameters
measured were generally within normal limits (Table 2).
DISCUSSION
The demonstration that the amyloid deposits in the proband
were composed of apoA-I and the complete concordance between
presence of the apoA-I gene mutation and development of
amyloidosis indicate that the mutation is the cause of disease in
this family. No tissue has become available for extraction and
characterization of amyloid fibrils but, based on the previous
published reports of hereditary apoA-I amyloidosis, it is likely that
the fibrils consist of the N-terminal fragment of the apoA-I
molecule [3, 5, 6, 12, 13].
The present, hitherto undescribed, mutation is the second
amyloidogenic apoA-I gene deletion mutation to be reported.
Remarkably it shares with the first one [6] and the three amyloi-
dogenic apoA-I point mutations [5], the effect of encoding a single
additional positive charge in the mature apoA-I protein sequence.
Wild type apoA-I forms senile amyloid in the pulmonary vascu-
lature of dogs [14] and in aortic atheroma plaques in humans [15],
but it is notable that all the known hereditary apoA-I amyloid
variants carry an extra positive charge on the N-terminal region of
the molecule. This is unlikely to be a coincidence. However,
although we have recently discussed possible mechanisms else-
where [5, 6], we still do not know the basis for the amyloidoge-
nicity of these variants.
The phenotype of the systemic amyloidosis in the present family
is interesting both for its differences from other hereditary apoA-I
Fig. 3. Liver biopsy of the proband (AA). Serial sections stained with (A) Congo red, showing birefringence (streaky white and dark areas) of the
amyloid deposits in polarized light; (B) antiserum to apoA-I, showing uptake on the amyloid deposits; (C) antiserum to apoA-I absorbed before use
with high density lipoprotein, showing specific abolition of the amyloid staining.
Proband
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Fig. 4. DNA sequence of the 5* end of exon 4 of the apoA-I gene of the
proband and of a normal control subject. The wild type sequence and the
residues encoded are GAG (Glu70) TTC (Phe71) TGG (Trp72) GAT
(Asp73). In addition, the proband showed a 9 base pair in-frame deletion,
at the position indicated by the arrowhead, of the bases shown above in
bold face type and indicated by the vertical bar on the normal sequence,
resulting in the sequence GA. . . T. This deletion results in loss of residues
Glu70Phe71Trp72, but residue Asp73 is retained, encoded by the remain-
ing sequence, GAT.
Table 1. Concordance of apoA-I mutation and amyloidosis
Subject
(age)
ApoA-I
genotype
Clinical
phenotype Histology
131I-SAP
scan
Proband (AA) del/wt renal transplant liver 1 11
(43) retinopathy rectum 2
Brother (KW) wt/wt well rectum 2 2
(43)
Sister (SP) del/wt hepatomegaly rectum 2 11
(47)
Cousin (JF) del/wt renal transplant rectum 11
(41) F retinopathy trace 1
Cousin (RF) wt/wt well rectum 2 2
(37) M
Cousin (BF) del/wt well rectum 2 11
(32) M
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amyloidoses and for its remarkably specific renal expression at the
clinical level. Despite massive hepatic and splenic deposits no
adverse clinical effects have been seen, even after greatly pro-
longed survival provided by renal transplantation. This differs
sharply from the fatal hepatic amyloidosis with little or no
clinical renal involvement of the Spanish apoA-I deletion/
insertion mutation [6]. Also, the heart is apparently spared in the
present family, in contrast to some individuals with the apoA-I
Trp50Arg variant [5], and yet the renal effects are much more
aggressive than those seen in one of the families with the apoA-I
Gly26Arg variant [4]. The very slow tempo of amyloid deposition
in the transplanted kidneys is also of interest.
Overall the present family confirms and extends the general
finding that in hereditary systemic amyloidosis there is only a
tenuous connection between the amyloid fibril protein, the under-
lying mutation within it and the clinical expression of the pheno-
type. This is often true even within families, as demonstrated here
where one affected individual (BF) with massive visceral deposits
is clinically normal and still has normal renal function, and
another has just hepatomegaly and some proteinuria, at ages
when other affected relatives had already long been transplanted
for end-stage renal failure. The mechanisms underlying tissue
distribution of amyloid and those by which it damages tissue and
organ function remain completely obscure.
JF BF RF AA
Heteroduplex
Wild-type
9bp Deletion
Fig. 5. Polyacrylamide gel (8%) electrophoresis
of the PCR product of exon 4 of the apoA-I
gene. The wild type allele is present in all
subjects and the additional abnormal allele with
the 9 base pair deletion is seen in individuals
with amyloid (AA, JF, BF) together with a
heteroduplex formed by the products in these
patients.
Normal mature apoAI (0)
Normal mature apoAI (–1)
1 2 3 4 5 6 7
Variant (+1) apoAI
Fig. 6. ApoA-I detected by immunoblotting
after isoelectric focusing of delipidated plasma.
Lane 1 (JF), 2 (BF), 4 (AA) and 5 (SP) are
affected family members; lane 3 (RF) and 6
(KW) are unaffected individuals; lane 7,
unrelated normal control. The most abundant
isoform of mature wild type apoAI is
designated 0 and its deaminated product as 21.
The apoA-I variant encoded by the deletion
mutation migrates, as predicted from the
derived amino acid sequence, with an extra
positive charge, 11.
Table 2. Apolipoprotein and lipid analyses
Subject Genotype
ApoA-I
100–170 mg/dliter
ApoB
60–120 mg/dliter
Triglyceride
0.3–2.3
mmol/liter
Cholesterol
,5.2 mmol/liter
HDL-Chol
0.6–2.0 mmol/liter
LDL-Chol
,3.5 mmol/liter
AA del/wt 66 80 0.7 4.4 0.7 3.4
BF del/wt 39a 100a 2.3 6.4 0.6 4.7
SP del/wt 76 70 9.7 4.0 1.0 2.7
JF del/wt 87 117 1.1 4.7 0.8 3.4
KW wt/wt 91 87 9.9 4.1 0.8 2.9
RF wt/wt 84 75 1.6 5.3 1.1 3.5
Normal ranges are shown.
a turbid specimen, results unreliable
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Finally, the present family illustrate dramatically the power of
SAP scintigraphy, which is safe and non-invasive, for diagnosis of
amyloid, especially in patients in whom rectal biopsy has been
negative despite the presence of massive visceral deposits.
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